Brief: Kyowa Kirin And MEI Pharma Announce Topline Data From Phase 2 MIRAGE Study Evaluating Zandelisib In Patients With Indolent B-Cell Non-Hodgkin's Lymphoma In Japan

Kyowa Kirin

18/11/2022 13:12

Nov 18 (Reuters) - Kyowa Kirin Co Ltd  4151.T :
    * KYOWA KIRIN AND MEI PHARMA ANNOUNCE TOPLINE DATA FROM
PHASE 2
MIRAGE STUDY EVALUATING ZANDELISIB IN PATIENTS WITH INDOLENT
B-CELL NON-HODGKIN'S LYMPHOMA IN JAPAN
    * MEI PHARMA INC - INTERIM DATA FROM PHASE II STUDY OF
ZANDELISIB
SHOWS 75.4% ORR IN JAPANESE PATIENTS WITH INDOLENT B-CELL NHL
    * MEI PHARMA INC - WITH 9.5 MONTHS MEDIAN DURATION OF
FOLLOW-UP, A
DISCONTINUATION RATE DUE TO ANY TREATMENT EMERGENT ADVERSE EVENT
WAS 14.8%

Source text for Eikon:  ID:nBw6xglCa 
Further company coverage:  4151.T